Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy

Intrahepatic cholangiocarcinoma (ICC) has limited therapeutic options and a dismal prognosis. Anti-PD-L1 immunotherapy combined with gemcitabine/cisplatin chemotherapy has recently shown efficacy in biliary tract cancers, but responses are seen only in a minority of patients. Here, we studied the ro...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jiang, Amoozgar, Zohreh, Liu, Xin, Aoki, Shuichi, Liu, Zelong, Shin, Sarah, Matsui, Aya, Pu, Zhangya, Lei, Pin-Ji, Datta, Meenal, Zhu, Lingling, Ruan, Zhiping, Shi, Lei, Staiculescu, Daniel, Inoue, Koetsu, Munn, Lance L., Fukumura, Dai, Huang, Peigen, Bardeesy, Nabeel, Ho, Won Jin, Jain, Rakesh. K., Duda, Dan G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901023/
https://www.ncbi.nlm.nih.gov/pubmed/36747853
http://dx.doi.org/10.1101/2023.01.26.525680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901023/
https://www.ncbi.nlm.nih.gov/pubmed/36747853
http://dx.doi.org/10.1101/2023.01.26.525680

Ejemplares similares